Nucleic Acid Therapies Market: Growth and Opportunities

Dublin, November 5, 2025 – The nucleic acid therapies market is experiencing growth due to the increasing prevalence of genetic and chronic diseases, the expansion of genomic research and development, and the growing adoption of RNA therapies. The nucleic acid therapies market report provides critical insights for strategists, marketers, and senior management to understand the dynamics of this rapidly growing market.

Valued at $6.01 billion in 2024, the global nucleic acid therapies market is expected to reach $12.24 billion by 2029. This represents a compound annual growth rate (CAGR) of 15.2%. Key drivers of growth include the demand for precision medicine, innovations in mRNA vaccine applications, and the expansion of nucleic acid-based therapy pipelines.

Significant trends contributing to the market expansion include the expansion of mRNA applications in oncology and rare diseases. Additionally, the integration of artificial intelligence and machine learning into RNA drug discovery processes, along with the development of targeted new and advanced delivery systems, can be counted among the innovations in this area. These trends present the potential to enhance the efficacy of nucleic acid therapies, representing a significant promise in the treatment of genetic diseases.

The rise in genetic and chronic diseases plays a significant role in the market's growth. The increasing prevalence of cardiovascular diseases, cancer, and autoimmune diseases necessitates innovative treatment solutions. Nucleic acid therapies are responding to this need by offering targeted and personalized interventions. For example, the UK-based Cystic Fibrosis Foundation has reported an increase in the number of registered cystic fibrosis patients, indicating a growing need for advanced gene-targeted therapies and applications.

Moreover, leading players in the industry continue to develop breakthrough therapeutic solutions. For instance, Ionis Pharmaceuticals Inc. made a significant stride in December 2024 by receiving FDA approval for TRYNGOLZ (olezarsen) for the treatment of familial chylomicronemia syndrome. Similarly, Novartis AG aimed to strengthen its RNA-targeted drug development capabilities and achieve rapid advancements in rare and chronic disease therapies by acquiring Regulus Therapeutics Inc. in June 2025.

Key players in this competitive market include Pfizer Inc., Sanofi S.A., Novartis AG, Moderna Inc., and BioNTech SE. These organizations are expanding RNA platforms by developing antisense oligonucleotide therapies to provide effective treatment.

Geographically, North America is the largest region in the market. However, the Asia-Pacific region is expected to be the fastest-growing. Alongside challenges such as global trade tensions, pharmaceutical companies are compelled to make strategic changes due to import tariffs on raw materials and laboratory equipment; this has resulted in developments such as the expansion of production capacities in India and Europe.

Supported by technological innovations and strategic partnerships, this industry is evolving dynamically. The nucleic acid therapies market is expanding not only in size but also in its capacity to provide groundbreaking, life-changing therapeutic solutions.